Ilsung Nam

Dr. Ilsung Nam

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2013 in Journal of Family and Economic Issues
Verified
Journal Article
Closed access
PDF file
TFTerri Friedline
Terri Friedline
INIlsung Nam
Ilsung Nam
VLVernon Loke
Vernon Loke

1 September 2012 in Children and Youth Services Review
Verified
Journal Article
Closed access
TFTerri Friedline
Terri Friedline
WEWilliam Elliott
William Elliott
INIlsung Nam
Ilsung Nam

30 June 2018 in Annals of Geriatric Medicine and Research
Verified
Journal Article
Open access
PDF file
INIlsung Nam
Ilsung Nam
Ilsung Nam. Ann Geriatr Med Res 2018;22:94-7. https://doi.org/10.4235/agmr.2018.22.2.94

28 February 2026 in Journal of Institute of Control, Robotics and Systems
Verified
Journal Article
Closed access
INIlsung Nam
Ilsung Nam
Recent studies examining the effects of social robots on depressive symptoms among older adults have reported mixed results, suggesting that depressive symptom patterns may follow distinct trajectories. The present study aimed to identify the trajectories of depressive symptoms and explore their associations with relevant variables. Participants were obtained from the Hyodol Project conducted in Seoul. A semi-parametric group-based modeling approach was used to identify the trajectories of depressive symptoms, decrease-increase using the Korean Geriatric Depression Scale (KGDS). Three distinct decrease-increase of depressive symptoms were identified: (1) steep decrease-increase (SDI), (2) gradual increase-decrease (GID), and (3) gradual decrease-increase (GDI). Factors associated with trajectory group membership included ease of robot use (B = 13.40 for SDI vs. GID; B = - 18.49 for GID vs. GDI), fun in talking to robots (B = 4.54 for SDI vs. GID; B = - 17.59 for GID vs. GDI), sleep problems (B = - 2.28 for SDI vs. GDI; B = - 2.30 for GID vs. GDI), and life management (B = 2.43 for SDI vs. GDI). These findings indicate that the trajectories of depressive symptoms among older adults using social robots are heterogeneous. Therefore, social robots should be integrated with systematic support systems that enhance ease of use and promote meaningful communication with older adults.

1 June 2014 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
TBTatiana Beketova
Tatiana Beketova
EAE. Alexandrova
E. Alexandrova
TNT. Novoselova
T. Novoselova
ESE. Sazhina
E. Sazhina
ENE. Nikolaeva
E. Nikolaeva
ENE. Nasonov
E. Nasonov
Background Rituximab (RTX) therapy is a treatment option in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Objectives Analysis of safety and efficacy of RTX in patients with ANCA-associated vasculitis treated in fourteen Russian clinical centers. Methods In 2011, Nasonova V.A. Research Institute of Rheumatology and Association of Rheumatologists of Russia created the NORMA project, a multicenter study whose objective is to gather information concerning the use of RTX in adult patients with systemic autoimmune diseases. Results 50 patients with ANCA-associated vasculitis treated with RTX are included in the NORMA registry (26 women and 24 men, mean age 40±15 years), including 35 patients with granulomatosis with polyangiitis, 13 with microscopic polyangiitis, 2 with eosinophilic granulomatosis with polyangiitis. 39 patients were cANCA/PR3 positive and 11 pANCA/MPO positive. 34% of patients had refractory ANCA-associated vasculitis, 36% high activity and/or signs of poor prognosis and 28% intolerance of standard agents. 25/50 patients were re-treatment at low-dose RTX (≤1000 mg) for partial responses/relapses (70%) or to maintain remission (30%). A total of 46 RTX subsequent cycles were completed, intervals between cycles averaged 6.4 months (range 4.5-11.3). Among 25 patients followed for more than 12 months, 23 complete and 2 partial responses were observed. Table 1 shows Birmingham vasculitis activity score (BVAS), CD19+ B-cells in peripheral blood and serum IgG levels at enrolment and after RTX treatment. Re-treatment was effective in controlling disease activity and did not result in progressive reduction in IgG. Ten patients (20%) had serious adverse events (including 6 infections and 3 neutropenia), all received a single cycle of RTX. Five patients died, two due to pneumonia and late onset neutropenia, two due to acute pulmonary embolism and one patient due to refractory vasculitis and pneumonia. BVAS, CD19+ B-cells and IgG levels at baseline, 3 and 6 months after each cycle of RTX Conclusions This uncontrolled observational study shows good tolerance and clinical efficacy of RTX in patients with ANCA-associated vasculitis and suggest, that low-dose RTX for the re-treatment is also effective. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.1960